Search

Displaying results 3931 - 3940 of 7603 in total
  1. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion … of patients with idiopathic myelofibrosis or essential thrombocythemia.

  2. Drug

    Bezafibrate

    go.drugbank.com/drugs/DB01393
    ApprovedInvestigational

    Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.

    Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  3. Drug

    Aluminum zirconium trichlorohydrex gly

    go.drugbank.com/drugs/DB11116
    ApprovedWithdrawn

    Aluminum zirconium trichlorohydrex gly is a common active ingredient in deodorant and antiperspirant products for the over-the-counter use.

  4. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder ...

    Categories: Antidepressive Agents Indicated for Depression, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  5. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

  6. Drug

    J147

    go.drugbank.com/drugs/DB13957
    Experimental

    [A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  7. Drug

    Melperone

    go.drugbank.com/drugs/DB09224
    Investigational

    Melperone has been used for a span of greater than 30 years in the European Union [L1316].

  8. Target

    Cytochrome P450 1A1

    go.drugbank.com/bio_entities/BE0009369
    EnzymeRat

    Displays different regioselectivities for polyunsaturated fatty acids (PUFA) hydroxylation (By similarity). Catalyzes the epoxidation of double bonds of certain PUFA (PubMed:20972997). … Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C15alpha

    Synonyms: Cytochrome P450 form 6
  9. Drug

    UM-171

    go.drugbank.com/drugs/DB19449
    Investigational

    UM-171 is a pyrimidoindole derivative that is an agonist of ex vivo hematopoietic stem cell expansion and thus supports the expansion of hematopoietic stem cells.[A264868, A264873]

    Salts: UM-171 dihydrobromide dihydrate
  10. Drug

    Sibutramine

    go.drugbank.com/drugs/DB01105
    ApprovedIllicitWithdrawn

    Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity.

    Products: SEMIT® CAPSULAS POR 15MG., SIBUTRAMINA MK 15 MG CAPSULAS